Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID Investigator Initiated Program Application (P01).

Date: September 6, 2012.

Place: Fernwood (Rockledge Campus), 10401 Fernwood Rd., Room 2C05, Bethesda, MD 20892, (Telephone Conference Call)

Contact Person: Kelly Y. Poe, Ph.D., Scientific Review Officer, NIAID Investigator Initiated Program Application, DEA/NIAID/NIH/DHHS, 6700–B Rockledge Drive, MDS–7616, Bethesda, MD 20892–7616, 301–451–2639, poeky@niaid.nih.gov.

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID Investigator Initiated Program Project Application (P01).

Date: September 12, 2012.

Time: 12:00 p.m. to 3:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Doubletree Hotel Bethesda, 8120 Wisconsin Avenue, Bethesda, MD 20814

Contact Person: James T. Snyder, Ph.D., Scientific Review Officer, NIAID Investigator Initiated Program Project Application, DEA/NIAID/NIH/DHHS, 6700–B Rockledge Drive, MDS–7616, Room # 3257, Bethesda, MD 20892, 301–435–1614, james.snyder@nih.gov.

DEPARTMENT OF HOMELAND SECURITY

National Institutes of Health

Center for Scientific Review; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Integrative and Functional Neurobiology.

Date: September 5, 2012.

Time: 2:30 p.m. to 4:30 p.m.

Agenda: To review and evaluate grant applications.

Place: Center for Scientific Review, 6701 Rockledge Drive, Bethesda, MD 20892, (Virtual Meeting).

Contact Person: Wei-Qín Zhao, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5181 MSC 7846, Bethesda, MD 20892–7846, 301–435–1236, zhao@csr.nih.gov.


Melanie J. Gray,
Program Analyst, Office of Federal Advisory Committee Policy.

(FR Doc. 2012–19717 Filed 8–10–12; 8:45 am)
paramount to ensure the effective and thorough decontamination of all material exiting the bio containment area within the facility. Rising health concerns and process efficiency/tourn-around time with the use of formaldehyde gas (the current fumigation method used against FMDV and ASFV) are key driving factors in validating an alternative fumigation method. The fumigation method(s) will ultimately be used to decontaminate sensitive equipment and electronics, other material within the bio containment area, sealed portions of the facility, biological safety cabinets and perform in-place decontamination of heating, ventilation, and cooling (HVAC) HEPA filtration systems. The role of the collaborator(s) in this CRADA will be to provide PIADC with the materials, equipment, and technological expertise to support accurate and reliable efficacy testing using VHP and ClO2. DHS S&T is seeking CRADA collaborators that own the technological components for, have the technological expertise in, and have proven track records of success in the fields of VHP and ClO2 decontamination validation studies. The proposed term of the CRADA can be up to eighteen (18) months.

DATES: Submit comments on or before September 14, 2012.

ADDRESSES: Mail comments and requests to participate to Doug Ports, (PO Box 848, Greenport, NY 11944). Submit electronic comments and other data to Doug Ports@hq.dhs.gov.


SUPPLEMENTARY INFORMATION:

Efficacy Testing Plan

The target agents (FMDV and ASFV) and test microorganisms (Bacillus subtilis, Vaccinia Virus, Geobacillus stearothermophilus, and potentially other commercially available spore strips) will be used to test the efficacy of VHP and ClO2 on various surfaces including balsa wood, stainless steel, glass, and paper. Phase I of the testing is set to take place at a federal laboratory facility against the test microorganisms, requiring successful results prior to moving on to Phase II. Phase II testing will take place at PIADC (Plum Island, NY) against both the test microorganisms and target agents. Phase I and Phase II efficacy testing will not require the VHP or ClO2 generators to enter the bio containment area; however, components or probes that do enter the bio containment area will need to be decontaminated using a validated method prior to removal. Testing and decontamination validation will take place using pre-approved methods agreed upon between federal and non-federal personnel. Mutual benefits to both federal and non-federal collaborators include the opportunity to support the Homeland Security Enterprise in protecting the United States from internal and external foreign animal disease threats and response capabilities. Specifically, DHS S&T is interested in validated alternatives to formaldehyde fumigation with respect to outbreak control, infection control, and decontamination for FMDV and ASFV releases. The collaborators will also have the opportunity to test their decontamination methods directly against live FMDV and ASFV at the only laboratory in the United States, and one of few in the world, that works with live FMDV. Efficacy testing data and results may be published in scientific journals by or under the guidance of federal personnel.

Period of Performance

Once CRADA collaborators have been selected, finalized Phase I testing is expected to take approximately 3 months. Contingent on Phase I testing results, Phase II testing is expected to take an additional 6 months and data consolidation, analysis, and results finalization is expected to take another 3 months following.

Selection Criteria

The Plum Island Animal Disease Center (PIADC) reserves the right to select CRADA collaborators for all, some, or none of the proposals in response to this notice. PIADC will provide no funding for reimbursement of proposal development costs. Proposals (or any other material) submitted in response to this notice will not be returned. Proposals submitted are expected to be unclassified.

PIADC will select proposals at its sole discretion on the basis of:

i. How well the proposal communicates the collaborators’ understanding of and ability to meet the CRADAs goals and proposed timeline

ii. How well the proposal addresses the following criteria:

a. Capability of the collaborator to provide equipment and materials for proposed Phase I and Phase II efficacy testing.

b. Capability of the collaborator to provide on-site and remote technological expertise, within a reasonable time period and for a reasonable duration, for Phase I and Phase II efficacy testing.

Participation in this CRADA does not imply the future purchase of any materials, equipment or services from the collaborating entities; however, non-Federal CRADA participants will not be excluded from any future PIADC procurements based solely on their participation in this CRADA.

Authority: CRADAs are authorized by the Federal Technology Transfer Act of 1986, as amended and codified by 15 U.S.C. 3710a. DHS, as an executive agency under 5 U.S.C. 105, is a Federal agency for the purposes of 15 U.S.C. 3710a and may enter into a CRADA. DHS delegated the authority to conduct CRADAs to the Science and Technology Directorate and its laboratories.

Dated: August 7, 2012

James Johnson,
Director, Office of National Laboratories.

[FR Doc. 2012–19723 Filed 8–10–12; 8:45 am]

BILLING CODE 9110–9F–P

DEPARTMENT OF HOMELAND SECURITY

Federal Emergency Management Agency

[Internal Agency Docket No. FEMA–4067–DR; Docket ID FEMA–2012–0002]

Colorado; Amendment No. 2 to Notice of a Major Disaster Declaration

AGENCY: Federal Emergency Management Agency, DHS.

ACTION: Notice.

SUMMARY: This notice amends the notice of a major disaster declaration for the State of Colorado (FEMA–4067–DR), dated June 28, 2012, and related determinations.

DATES: Effective Date: August 6, 2012.

FOR FURTHER INFORMATION CONTACT:

SUPPLEMENTARY INFORMATION: The notice of a major disaster declaration for the State of Colorado is hereby amended to include the Hazard Mitigation Grant Program for the following areas among those areas determined to have been adversely affected by the event declared a major disaster by the President in his declaration of June 28, 2012.

All counties in the State of Colorado are eligible to apply for assistance under the Hazard Mitigation Grant Program.

(1) The following Catalog of Federal Domestic Assistance Numbers (CFDA) are to be used for reporting and drawing funds: 97.030, Community Disaster Loans; 97.051, Coral